• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on therapeutic targets >The Hedgehog signalling pathway as a therapeutic target in early breast cancer development.
【24h】

The Hedgehog signalling pathway as a therapeutic target in early breast cancer development.

机译：刺猬信号通路是早期乳腺癌发展中的治疗靶点。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The Hedgehog (Hh) signalling pathway is a highly conserved developmental pathway, which plays critical roles in patterning of the embryo through epithelial to mesenchymal signalling and the maintenance of stem cells in the adult organism. There is increasing evidence that this pathway is dysregulated in many malignancies, including breast cancer. While there has been a significant decrease in mortality from breast cancer, a number of treatment challenges remain, particularly in those tumours which develop resistance to endocrine-based therapy, or which lack expression of hormone or c-erbB2/HER2 receptors. Therapeutic manipulation of the Hh pathway as a potential cancer therapy is attracting great interest, with preclinical studies and clinical trials underway in a range of malignancies. This review highlights important recent developments that affect the potential of the Hh pathway as a novel therapeutic target in early breast cancer.
机译：刺猬（Hh）信号传导途径是高度保守的发育途径，在上皮到间充质信号传导以及维持成体生物中干细胞的胚胎形成模式中起着关键作用。越来越多的证据表明，该途径在包括乳腺癌在内的许多恶性肿瘤中均失调。尽管乳腺癌的死亡率已显着降低，但仍存在许多治疗挑战，尤其是那些对内分泌治疗产生抗药性或缺乏激素或c-erbB2 / HER2受体表达的肿瘤。 Hh途径作为一种潜在的癌症治疗方法的治疗性操作引起了人们的极大兴趣，有关一系列恶性肿瘤的临床前研究和临床试验正在进行中。这篇综述强调了重要的最新进展，这些进展影响了Hh途径作为早期乳腺癌新治疗靶标的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号